Technology evaluation: Belatacept, Bristol-Myers Squibb.
Bristol-Myers Squibb is developing belatacept, a soluble fusion protein of the B7-binding domain of CTLA4 with amino acid changes A29Y and L104E and an Ig tail, which inhibits lymphocyte co-stimulation through CD28, for the potential treatment of solid organ transplant rejection. Belatacept is currently undergoing phase III clinical trials.
Vanhove
Bernard
B
INSERM U643, Institut de Transplantation et de Recherche en Transplantation, 30 Bld J Monnet, 44093 Nantes, France. Bernard.Vanhove@univ-nantes.fr
Soulillou
Jean-Paul
JP
D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D060908:CTLA-4 Antigen; D017322:Clinical Trials, Phase II as Topic; D005818:Genetic Engineering; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation; D016032:Randomized Controlled Trials as Topic
D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D007166:Immunosuppressive Agents